Comparison of Coronary Artery Bypass Grafting with Percutaneous Coronary Intervention for Unprotected Left Main Coronary Artery Disease by Kawecki, Damian et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 1   January 2012 58
Original Article
http://dx.doi.org/10.3349/ymj.2012.53.1.58
pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 53(1):58-67, 2012
Comparison of Coronary Artery Bypass Grafting  
with Percutaneous Coronary Intervention for Unprotected  
Left Main Coronary Artery Disease
Damian Kawecki, Beata Morawiec, Marcin Fudal, Wojciech Milejski,  
Wojciech Jachec ‘, and Ewa Nowalany-Kozielska
2nd Department of Cardiology, Zabrze, Medical University of Silesia, Katowice, Poland.
Received: January 31, 2011
Revised: March 9, 2011
Accepted: March 9, 2011
Corresponding author: Dr. Damian Kawecki,
2nd Department of Cardiology, Zabrze, Medical 
University of Silesia, Katowice, 10 M. Curie-
Skłodowskiej Str., 41-800 Zabrze, Poland.
Tel: 48322711010, Fax: 48322711010
E-mail: d.kawecki@interia.pl
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2012
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Purpose: Coronary artery bypass grafting (CABG) is the optimal treatment option 
for left main coronary artery disease (LMCAD). However, LMCAD remains a con-
stant topic of discussion between cardiac surgeons and interventional cardiologists. 
The aim of this study was to assess the efficacy of LMCAD treatments by compar-
ing the mid-term outcomes of CABG and percutaneous coronary intervention (PCI) 
using bare metal stents or drug-eluting stents (DESs). Materials and Methods: The 
study population was comprised of 199 consecutive patients admitted with unpro-
tected LMCAD. All of the patients were assigned to PCI (88 patients) or CABG 
(111 patients). The primary clinical end point indicated death, stroke of acute coro-
nary syndrome (ACS). Results: Patients assigned to PCI were at higher operative 
risk than patients scheduled for CABG (6.49±4.09 vs. 4.81±2.67, p=0.0032). Com-
parison of the group that received DESs with the CABG group did not reveal any 
differences in major adverse cardio-cerebral events (MACCE) occurrence (21% vs. 
16%, p=NS). Patients in the CABG and PCI groups died with similar frequency (11% 
vs. 16%, p=NS). The mortality rate in the CABG group was higher than among those 
treated with DES (11% vs. 3%, p=0.049). The rate of ACS was higher in the PCI 
group than in the CABG group (13% vs. 4%, p=0.016). Conclusion: Despite the 
fact that patients treated with PCI were at higher operative risk, PCI with DES was 
shown to be comparable to CABG in terms of mortality, stroke and ACS. However, 
the frequency of repeat revascularizations remains a constant concern with PCI.
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INTRODUCTION
Left main coronary artery disease (LMCAD) incidence among patients undergo-
ing coronary angiography is estimated to be up to 6%.1 Although uncommon, 
LMCAD is a constant topic of discussion between cardiac surgeons and interven-
tional cardiologists. This discussion began in 1975, when Gorlin and Cohen2 first 
compared a surgical approach for LM stenosis to any other treatment options and 
reported that coronary artery bypass grafting (CABG) showed significant benefits CABG vs. PCI for Unprotected LMCAD
Yonsei Med J   http://www.eymj.org   Volume 53   Number 1   January 2012 59
surgery and grounds for reconsidering LMCAD treatment.
The aim of the present study was to assess the efficacy of 
left main coronary artery stenosis treatments by comparing 
the mid-term outcomes of CABG and PCI with BMSs or 
DESs.
MATERIALS AND METHODS
Study population
The study population was comprised of 199 consecutive pa-
tients admitted between 2005 and 2008 with unprotected 
LMCAD. All of the patients were assigned to undergo inva-
sive treatment; they were assigned to either PCI (88 patients) 
or CABG (111 patients) after a profound review of their 
baseline characteristics (Table 1), current standards of care in 
treatment for LMCAD and identification of patients at high 
risk using the European System for Cardiac Operative Risk 
Evaluation (EuroSCORE), as previously described.3 An ex-
perienced interventional cardiologist and a practiced cardi-
ac surgeon examined each patient’s case details to deter-
over medical therapy in the treatment of LMCAD. This re-
port began the search for alternatives to CABG in LMCAD. 
The first attempts with percutaneous coronary intervention 
(PCI) with bare metal stents (BMSs) in LM stenosis were 
less invasive than CABG. However, overall high mortality 
and revascularization rates with BMSs have led the Ameri-
can Heart Association and the American College of Cardi-
ology, followed by the European Society of Cardiology, to 
establish firm guidelines stating that CABG is the optimal 
treatment option for LMCAD. By giving these pre-drug 
eluting stents (DESs) a class III designation, PCI was made 
only available to patients disqualified from all other possi-
ble methods of treatment. Since the introduction of DES, 
these guidelines have remained unchanged. However, as a 
consequence of advances in and research on stent technolo-
gy, combined with the expansive development of interven-
tional cardiology, a debate has arisen about the optimization 
of a medical approach to this severe coronary disease. The 
ability of DESs to reduce restenosis as compared to BMSs 
may encourage their use in LMCAD. Interventional treat-
ment in LM stenosis has become a valuable alternative to 
Table 1. Baseline Characteristics
Overall cohort (n=199) Cohort 1 (n=159) Cohort 2 (n=145)
CABG 
(n=111)
PCI 
(n=88) p value CABG 
(n=111)
BMS 
(n=48) p value CABG 
(n=111)
DES 
(n=34) p value
Age 65.6±9.1 66.8±10.4 NS 65.6±9.12 68.83±9.67 p=0.005 65.6±9.1 63.6±10.6 NS
Men  81 (73) 60 (68) NS 81 (73) 34 (71) NS 81 (73) 23 (68) NS
Hypertension  80 (72) 66 (75) NS 80 (72) 36 (75) NS 80 (72) 25 (74) NS
Diabetes mellitus 34 (31) 26 (30) NS 34 (31) 16 (33) NS 34 (31)   6 (18) NS
Dyslipidemia 45 (41) 36 (41) NS 45 (41) 18 (38) NS 45 (41) 16 (47) NS
Peripheral vascular   
  disease 9 (8) 8 (9) NS 9 (8) 4 (8) NS 9 (8) 3 (9) NS
Carotid arteries 
  disease 18 (16) 3 (3) p<0.001 18 (16) 3 (6) p=0.031 18 (16) 0 (0) p=0.007
Current smoker  19 (17) 14 (16) NS 19 (17)   8 (17) NS 19 (17)   4 (12) NS
Former smoker  48 (43) 30 (34) NS 48 (43) 17 (35) NS 48 (43) 11 (32) NS
Family history 38 (34) 30 (34) NS 38 (34) 15 (31) NS 38 (34) 12 (35) NS
Previous myocardial 
  infarction  30 (27) 31 (35) NS 30 (27) 18 (38) NS 30 (27) 10 (29) NS
History of PCI 12 (11) 25 (28) p<0.001 12 (11)   5 (10) NS 12 (11)   6 (18) p<0.001
EF 47.9±10.2 41.7±13.4 p<0.001 47.9±10.2 39.3±14.4 p<0.001 47.9±10.2 45.7±10.7 NS
Clinical presentation
    Chronic stable 
      angina 64 (58) 42 (48) NS 64 (58) 14 (29) p<0.001 64 (58) 24 (71) NS
    Unstable angina 27 (24) 19 (22) NS 27 (24) 12 (25) NS 27 (24)   7 (21) NS
    Myocardial 
      infarction 20 (18) 27 (31) p=0.019 20 (18) 22 (46) p<0.001 20 (18) 3 (9) NS
EuroSCORE 4.81±2.67 6.49±4.09 p<0.001 4.81±2.67 7.6±4.27 p<0.001 4.81±2.67 4.76±3.36 NS
BMS, bare metal stent; CABG, coronary artery bypass grafting; DES, drug-eluting stent; EF, ejection fraction; PCI, percutaneous coronary intervention; NS, 
not significant.      
Values are n (%) or mean±SD.Damian Kawecki, et al.
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but three patients, who required a transradial approach due 
to peripheral vascular disease. The angiographic findings 
included isolated LMCAD (single left main stenosis) or 
LMCAD combined with one-, two- or three-vessel disease 
(1-VD, 2-VD, 3-VD). The stenting technique was chosen 
based on the location of the lesion. Ostium or trunk LM dis-
ease without bifurcation lesions were mainly treated with a 
single stent. Lesions involving the distal segment of the LM 
or bifurcation were treated with T-stenting, provisional T-
stenting or the kissing-balloon technique. The operator de-
cided between the use of a BMS or DES and chose the initial 
inflation pressure for high-pressure stent deployment (usually 
16 atm), as well as the optimal stent apposition. Stent apposi-
tion was not evaluated by intravascular ultrasound (IVUS) 
because the department only became equipped with this 
technology in 2008. If the operator decided that the stent 
had been deployed incorrectly, optimal stent apposition was 
achieved by post-dilation with additional balloons. Percuta-
neous old-balloon angioplasty (POBA) was performed in 
patients with a history of PCI in the LM. The procedural 
PCI characteristics are listed in Table 3. Glycoprotein IIb/
IIIa inhibitors and an intra-aortic balloon pump (IABP) 
were used in clinically indicated situations. The medical 
therapy for each patient who underwent PCI consisted of a 
loading dose of clopidogrel (300 or 600 mg p.o.) and unfrac-
tioned heparin (70 IU/kg i.v.). After the procedure, each pa-
tient was prescribed acetylsalicylic acid (75 mg/day) indefi-
nitely, clopidogrel (75 mg/day) for at least twelve months, 
and other medications according to the judgment of the pa-
tient’s physician.
The definition of procedural PCI success was a throm-
mine how to optimize their care. Patients who underwent 
PCI were those who were at a higher risk for complications 
from CABG, refused surgical treatment, had limited life ex-
pectancy, or were thought by the surgeon to be unsuitable 
for CABG.
Due to the many differences between BMSs and DESs, 
each of these groups was compared with the CABG group 
separately. For that reason, two subgroups were created: co-
hort 1 - CABG vs. BMS and cohort 2 - CABG vs. DES. 
The enrollment criterion was unprotected LMCAD occur-
rence, which was defined as ≥50% diameter LM stenosis 
on coronary angiography. The left main was considered to 
be unprotected when there was no coronary artery bypass 
graft to the left anterior descending artery (LAD) and/or the 
circumflex artery (Cx). Patients with concomitant valve fail-
ure requiring surgical intervention and those having already 
undergone bypass surgery with a graft to LAD and/or Cx 
were not enrolled in this study.
The diagnostic process was similar for each of the pa-
tients in the study population and included anamnesis, physi-
cal examination, basic laboratory tests, a standard 12-lead 
electrocardiography, echocardiographic examination and 
coronary angiography. The cardiac enzyme analysis was 
not included in the study design because they were mea-
sured only when there was clinical suspicion of ischemia.
Procedures
PCI 
Percutaneous coronary intervention was performed using 
the Seldinger technique and a transfemoral approach in all 
Table 2. Angiographic Data
Overall cohort (n=199) Cohort 1 (n=159) Cohort 2 (n=145)
CABG 
(n=111)
PCI 
(n=88) p value CABG 
(n=111)
BMS 
(n=48) p value CABG 
(n=111)
DES 
(n=34) p value
LM stenosis  67.3±15.4 72.6±16.6 p=0.011 67.3±15.4 39.3±14.5 p<0.001 67.3±15.4 64.7±14.1 NS
Isolated LMCAD  2 (2) 8 (9) p=0.008 2 (2) 4 (8) NS 2 (2)   4 (12) p=0.014
Coronary artery disease
    LM+1-VD 16 (14) 25 (28) p=0.008 16 (14)   6 (13) NS 16 (14) 17 (50) p<0.001
    LM+2-VD 27 (24) 21 (24) NS 27 (24) 14 (29) NS 27 (24)   6 (18) NS
    LM+3-VD 66 (60) 34 (39) p=0.002 66 (60) 24 (50) NS 66 (60)   7 (21) p<0.001
LMCAD location
    Ostial 22 (20) 42 (48) p<0.001 22 (20) 22 (46) p<0.001 22 (20) 17 (50) p<0.001
    Mid 14 (13) 20 (23) p=0.03 14 (13) 10 (21) NS 14 (13)   8 (24) NS
    Distal bifurcation 97 (87) 52 (59) p<0.001 97 (87) 28 (58) p<0.001 97 (87) 18 (53) p<0.001
BMS, bare metal stent; CABG, coronary artery bypass grafting; DES, drug-eluting stent; LMCAD, left main coronary artery disease; PCI, percutaneous coro-
nary intervention; VD, vessel disease; NS, not significant.     
Values are n (%) or mean±SD.CABG vs. PCI for Unprotected LMCAD
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es of earlier end-point occurrence. After this time, angina se-
verity was assessed based on the Canadian Cardiovascular 
Society (CCS) Classification and dyspnea status according to 
the New York Heart Association (NYHA) Classification.
Statistics
All statistical tests were performed with Statisctica software, 
version 9PL (StatSoft Inc., Tulsa, OK, USA) and MedCalc 
(MedCalc Software, Mariakerke, Belgium). Differences re-
garding major adverse cardio-cerebral events (MACCE), 
baseline and angiographic characteristics for each cohort 
analysis as well as differences in PCI technique between 
DES and BMS groups were assessed by two fractions test 
and a chi-square test. In order to compare length of stay, fol-
low-up duration, EuroScore, left ventricle ejection fraction 
(EF), the severity of LM stenosis and stent dimentions be-
tween groups, the variables were checked for normality of 
distribution (Shapiro-Wilks test), and means (±SD) were cal-
culated then compared using the nonparametric Mann-Whit-
ney and Kruskal-Wallis tests. In order to identify independent 
predictors of MACCE, a multivariate logistic regression 
model was created with the use of baseline clinical, angio-
bolysis in myocardial infarction flow of grade 3 in the treat-
ed vessel and a final residual stenosis of <30% as well as no 
dissection and the absence of clinical end points.
CABG
Coronary artery bypass grafting was routinely performed un-
der cardiopulmonary bypass after sternotomy using the left 
internal mammary artery as a graft for LAD, vena saphena 
magna as a graft for Cx and cold potassium cardioplegia.
End points
The primary clinical end point was death of cardiac origin, 
stroke, and acute coronary syndrome (ACS). ACS was a 
composite of target vessel revascularization (TVR) and 
acute myocardial infarction (AMI) or unstable angina (UA) 
with a culprit vessel other than the LM. AMI and UA were 
diagnosed according to the European Society of Cardiology   
criteria for ACS. TVR was defined as a repeated lumen ste-
nosis in a previously treated LM that required reinterven-
tion (within the stent, within 5 mm proximal and/or distal to 
the stent and within the ostium of LAD and/or Cx).
Follow-up was approximately 12 months or shorter in cas-
Table 3. Procedural Characteristics
CABG
LIMA-to-LAD graft  111 (100)
PCI
BMS 48 (54)
DES  34 (39)
POBA  6 (7)
Direct stenting  52 (59)
Predilatation  30 (34)
IABP  10 (11)
IIbIIIa inhibitor  10 (11)
PCI of other coronary lesions   41 (47)
Mechanical ventilation   3 (3)
BMS DES p value
PCI technique
    Single stent 18 (44) 16 (47) NS
    T-stenting 29 (18)   5 (15) NS
    Provisional T-stenting 21 (38) 13 (38) NS
    Kissing balloons 26 (23)   8 (24) NS
Stents per patient     1.21±0.46   1.15±0.36 NS
Final diameter of stent (mm)    3.69±0.57   3.54±0.38 NS
Total stent lenght (mm) 16.88±935 15.79±6.73 NS
Initial inflation pressure (Atm) 14.13±3.94 14.44±3.14 NS
BMS, bare metal stent; CABG, coronary artery bypass grafting; DES, drug-eluting stent; IABP, intra-aortic balloon pump; LAD, left anterior 
descending; LIMA, left internal mammary artery; PCI, percutaneous coronary intervention; POBA, percutaneous old-balloon angiography; 
NS, not significant. 
Values are n (%) or mean±SD.Damian Kawecki, et al.
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analysis. For DES patients, the mean preoperative risk was 
4.76±3.36. High-risk patients (EuroSCORE ≥6) constituted 
24% of the DES patients and 14% of the CABG patients.
Angiographic characteristics
Overall cohort
Percutaneous interventions were performed in patients pre-
senting with more severe LM stenosis (p=0.011). Coronary 
angiography revealed significant differences in the occur-
rence of isolated LMCAD (9% of PCI patients vs. 2% of 
CABG patients, p=0.008), 1-VD (28% vs. 14%, respectively, 
p=0.008) and 3-VD (39% vs. 60%, respectively, p=0.002). 
Patients also differed significantly in terms of LMCAD lo-
cation. Patients with isolated ostial or mid-body disease 
qualified more frequently for PCI (p<0.001 and p=0.03, re-
spectively); for those patients with stenosis in the distal bifur-
cation, CABG was the preferred treatment option (p<0.001).
Cohort 1
Patients who received BMSs in the PCI procedure suffered 
from more severe LM stenosis than CABG patients (p< 
0.001). Distal-bifurcation stenosis was more frequent in the 
CABG group (p<0.001) and ostial left main stenosis was 
more frequent in the BMS group (p<0.001). 
Cohort 2
Patients receiving DES also had a higher occurrence of iso-
lated LMCAD and 1-VD (p=0.014 and 0<0.001, respective-
ly) as well as a higher occurrence of ostial stenosis of the 
LM (p<0.001). Patients undergoing CABG more frequent-
ly had 3-VD and distal-bifurcation stenosis (p<0.001 and 
p<0.001, respectively). 
Procedural characteristics 
PCI
The procedural characteristics are listed in Table 3. The 
procedural success rate was 98% in the PCI group. Direct 
stenting was performed in 52 patients; 30 patients received 
stents after predilatation and six patients underwent POBA. 
The BMS subgroup consisted of 48 patients, while the DES 
group consisted of 34 patients. On average, 1.21±0.46 
BMSs and 1.15±0.36 DESs were implanted with a total 
stent length of 16.88±9.35 mm for BMSs and 15.79±6.73 
mm for DESs. IABP was used in 10 patients (11%), and 
three patients (3%) required the use of mechanical ventila-
graphic and procedure-related characteristics. A significance 
level of 0.05 was used throughout the study. 
RESULTS
Baseline characteristics
Overall cohort
Between January 2005 and December 2008, a total of 199 
patients were enrolled in this study. Of these patients, 111 
were referred for CABG, 88 underwent PCI with either 
BMS (48 patients) or DES (34 patients), and 6 received 
POBA. The baseline clinical and angiographic data are pre-
sented in Table 1 and 2. Patients in the CABG group were 
characterized by a higher left ventricle EF of 47.9±10.2%, as 
compared to 41.7±13.4% in the PCI group (p<0.001). The 
CABG group also suffered from carotid artery disease 
more frequently than PCI patients (p<0.001). Compared to 
the CABG patients, those in the PCI group were more likely 
to have a history of PCI (p<0.001) and myocardial infarction 
as presenting symptoms (p=0.019).The average EuroS-
CORE was 4.81±2.67 in the CABG group and 6.49±4.09 
in the PCI group (p<0.001). In 14% of surgery patients and 
44% of PCI patients, a EuroSCORE of  ≥ 6 was assessed. 
Cohort 1
The analysis of cohort 1 showed a significantly higher oc-
currence of carotid artery disease (p=0.031) and higher left 
ventricular ejection fraction (p<0.001) in the CABG than in 
the BMS group. Patients who received BMSs in the PCI 
procedure were older than patients in the surgery group 
(p=0.005). Patients receiving BMSs were also more likely 
to present with chronic stable angina (p<0.001) and myo-
cardial infarction (p<0.001). The average EuroSCORE for 
BMS patients was 7.6±4.27 and 4.81±2.67 in the surgery 
group (p<0.001). A EuroSCORE of ≥6 was found in 52% 
of BMS patients and in 14% of CABG patients.
Cohort 2
The comparison of the CABG and DES groups revealed 
that there were no cases of carotid artery disease among pa-
tients in the PCI with DES group, while 16% of CABG pa-
tients were diagnosed with this disease (p=0.007). Patients 
with a history of PCI were significantly more common in 
the DES group (p<0.001). No differences regarding clinical 
presentation or EuroSCORE were observed in the cohort 2 CABG vs. PCI for Unprotected LMCAD
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termine the independent MACCE-related factors and their 
significance. The adjusted data were method of treatment, 
variables listed in Table 1, 2 and 3, in-hospital length of 
stay and follow-up. Fig. 1 presents the outcomes.
For the overall cohort, the significant independent MAC-
CE-related factors were diabetes mellitus and previous stroke, 
while EF and dyslipidemia lowered the risk of MACCE. 
Among patients referred to surgery, the analysis indicated 
peripheral vascular disease to be a significant predictor of 
MACCE, and EF to be a factor of freedom from MACCE.
The significant independent MACCE predictors for PCI 
patients were diabetes mellitus, IABP, history of stroke and 
age, EF, dyslipidemia and chronic stable angina decreased 
the probability of MACCE in those patients. In the BMS 
group, dyslipidemia, EF and chronic stable angina appeared 
to lower the end-point risk. In the DES group, diabetes mel-
litus and 3-VD were the independent factors significantly 
related to MACCE.
Clinical symptoms 
Post-procedural CCS Class and NYHA Class in the CABG 
group were similar to the scores of PCI patients at follow-
up (p=0.171 for CCS and p=0.094 for NYHA). There were 
no differences between groups in cohort 1 and cohort 2 re-
garding the severity of angina or dyspnea. CABG patients 
stayed in the hospital longer than patients with BMS im-
plantation (p=0.042) and also longer than patients who un-
derwent PCI (p=0.029) (Table 4).
DISCUSSION
   
This study compared the mid-term outcomes of PCI and 
CABG in unprotected LMCAD. It showed that the higher 
tion. A glycoprotein IIb/IIIa inhibitor was given to 10 pa-
tients (11%).
CABG
All 111 patients scheduled for bypass surgery received the 
LIMA-to-LAD graft (100%).
Follow-up
The outcomes are summarized in Table 4. The mean follow-
up was 13.48±7.68 months for the CABG group, which was 
significantly different from the overall PCI group (11.44± 
7.21 months, p=0.038) and from the BMS group (10.56± 
7.46 months, p=0.002). Patients who received DES implan-
tation were followed for 13.21±7.12 months.
MACCE
In the unadjusted analysis, the combined clinical end point 
(MACCE) at follow-up was higher in the PCI group than in 
the CABG group (p=0.019). No difference in MACCE oc-
currence was observed between the CABG and DES pa-
tients, while significantly more patients developed MACCE 
after BMS implantation compared to bypass surgery (p= 
0.010). Individual components of the combined clinical end 
point revealed some heterogeniety. Patients in the CABG 
and PCI groups died with equal frequency. However, the 
mortality rate in CABG group was lower than that of BMS 
implantation (p=0.015) but higher than DES (p=0.049). In 
the CABG group the rate of ACS was lower than in the PCI 
group (p=0.016). There were two cases of stroke in patients 
after CABG and none in the PCI patients (p=0.030). TVR 
occurred in two patients from the DES group (6%) and in 
four patients in the BMS group (8%) for a total TVR of 7% 
in the PCI patients, compared with 4% TVR  after CABG.
Multivariate logistical regression analysis was used to de-
Table 4. Outcomes
Overall cohort (n=199) Cohort 1 (n=159) Cohort 2 (n=145)
CABG 
(n=111)
PCI 
(n=88) p value CABG 
(n=111)
BMS 
(n=48) p value CABG 
(n=111)
DES 
(n=34) p value
In-hospital length 
  of stay (days) 12.69±6.28 11.57±7.65 p=0.029 12.69±6.28 11.94±9.24 p=0.042 12.69±6.28 10.74±4.59 NS
Follow-up (months) 13.48±7.68 11.44±7.21 p=0.038 13.48±7.68 10.56±7.46 p=0.002 13.48±7.68 13.21±7.12 NS
MACCE 18 (16) 24 (27) p=0.019 18 (16) 17 (35) p=0.010 18 (16) 7 (21) NS
Death  12 (11) 14 (16) NS 12 (11) 13 (27) p=0.015 12 (11) 1 (3) p=0.049
Stroke 2 (2) 0 (0) p=0.030 2 (2) 0 (0) NS 2 (2) 0 (0) NS
ACS   4 (4) 10 (11) p=0.016 4 (4) 4 (8) NS 4 (4) 6 (18) p=0.019
ACS, acute coronary syndrome; BMS, bare metal stent; CABG, coronary artery bypass grafting; DES, drug-eluting stent; MACCE, major adverse cardio-
cerebral events; PCI, percutaneous coronary intervention; NS, not significant. 
Values are n (%) or mean±SD.Damian Kawecki, et al.
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demonstrated, and CABG was superior to BMS in terms of 
mortality rates and total MACCE occurrence.
The observations comparing BMS implantation for LM 
stenosis with surgical revascularization are consistent with 
the pre-DES era studies, which suggested greater benefit 
from CABG than from PCI in LMCAD treatment.10 The 
survival rate for BMS patients in our study (73%) is in ac-
cordance with the outcomes presented in 1997 by Ellis, et 
al.,11 where patients diagnosed with LMCAD and disquali-
fied from surgery were treated with BMS-supported PCI, 
balloon angioplasty or atherectomy. The authors reported 
an event-free survival of 71±5% in treated patients. Similar 
results were also observed a few years later.12-14 The current 
guidelines15 reflect those findings and state that CABG is 
the optimal treatment option for LM stenosis, mainly be-
cause of its well-documented and durable survival advan-
tage.16-18 The introduction of DES to interventional practice 
occurrence of MACCE in the PCI group than in the CABG 
group (27% vs. 16%, p=0.019) may be due to the higher 
pre-operative risk of death in the PCI group (6.49±4.09 vs. 
4.81±2.67 among CABG patients, p<0.001). Similar obser-
vations of the incidence of MACCE were also reported by 
the SYNTAX trial investigators (17.8% in the PCI group vs. 
12.1% in the CABG group, p=0.0015).4 Some studies have 
found equal MACCE rates for PCI and CABG groups.5-8 
However, a trend towards a higher risk of MACCE among 
patients who underwent PCI with DES was noticed.9 In 
some studies, CABG patients had a slightly higher MAC-
CE occurrence.5,7 The outcomes of this study for PCI patients 
differed according to the type of stent implanted. However, 
the superiority of CABG over PCI in terms of MACCE oc-
currence suggests that the components of MACCE and 
subgroup analyses should be interpreted carefully. No sur-
vival benefit from BMS implantation over surgery was 
Fig. 1. Outcomes. DES, drug-eluting stent; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; BMS, bare metal stents; CI, con-
fidence interval; EF, ejection fraction; IABP, intra-aortic balloon pump; LM+3VD, left main combined with three-vessel disease; MACCE, major adverse car-
dio-cerebral events; OR, odds ratio.
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EF Dyslipidemia Diabetes 
mellitus
History of 
stroke
p<0.001 p<0.001 p=0.015 p=0.046
0.937
0.286
2.726 4.765
Overall cohort OR, CI 95%
0.001
0.01
0.1
1
10
EF Dyslipi-
demia
Diabetes 
mellitus
IABP History 
of stroke
Chronic
stable 
angina
Age
p<0.001 p=0.018 p=0.022 p=0.030 p=0.034 p=0.036 p=0.044
0.932
0.258
3.231 4.658
11.81
0.298
1.052
PCI group OR, CI 95%
0.001
0.01
0.1
1
10
Diabetes mellitus LM+3VD
p=0.003 p=0.021
65 10.667
DES group OR, CI 95%
0.001
0.01
0.1
1
10
EF Peripheral vascular disease
p=0.006 p=0.016
0.935 6.433
CABG group OR, CI 95%CABG vs. PCI for Unprotected LMCAD
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pothesis and was not proven by any statistical method. 
Based on multivariate logistic-regression analysis, indepen-
dent stroke, death and ACS (MACCE)-related factors and 
their levels of significance are presented in Table 4. The 
analysis conducted on the general cohort indicated that dia-
betes mellitus and previous stroke were strong independent 
predictors of MACCE, while left ventricle ejection fraction 
and dyslipidemia appeared to lower the risk of MACCE. 
The controversial finding concerning dyslipidemia may be 
related to previous chronic drug treatment for this disease 
(for example, a pleiotropic statin effect), and its potentially 
positive effect on the outcome and decrease in MACCE 
risk. The influence of diabetes mellitus on MACCE occur-
rence for the general cohort is in accordance with previous 
papers.7,24 The analysis did not indicate any method of treat-
ment (CABG or PCI) to be a predictor of MACCE. The lo-
gistic regression model was also applied to each of the sub-
groups separately. Diabetes mellitus appeared to be one of 
the predictors of MACCE in the analysis of PCI, DES and 
BMS patients, while it was not a significant factor for MAC-
CE in the CABG group. These findings are not consistent 
with the results of the Bypass Angioplasty Revasculariza-
tion Investigation trial,25 in which the 7-year mortality rate 
of treated diabetics in the registry was equal in the PCI and 
CABG groups. Notwithstanding those observations, accord-
ing to the clinical recommendations, the preferred treatment 
option for patients presenting with chronic stable angina 
and multivessel CAD or LMCAD-especially with concom-
itant diabetes mellitus-is surgical revascularization.26
It should be noted that interpretation of the complex 
MACCE etiology based solely on logistic regression out-
comes is incomplete. The complexity of the patient’s clini-
cal status and the procedural characteristics should be in-
cluded in the analysis as operator- and guideline-dependent 
factors.
In order to identify patients at high risk and predict the 
risk of mortality, we used the EuroSCORE. Patients in the 
PCI group were revealed to be at higher pre-operative risk 
than patients referred to surgery. The comparison of EuroS-
COREs between CABG and DES patients showed equal 
scores in the two groups. Notwithstanding the recommen-
dations for high-risk patients who ought to be treated surgi-
cally, there is still a divergence in the methods applied and 
outcomes reported by many different investigators. In sev-
eral prior studies, according to the recommendations, pa-
tients with more significant comorbidities were scheduled 
for CABG;21,27 however, some other authors have reported 
modified the approach to LM stenosis treatment and gave 
solid ground reconsidering the management of this severe 
coronary disease.
In this study, patients who underwent PCI with DES and 
patients referred to CABG had comparable levels of pre-
operative risk. Equal MACCE occurrence in these groups 
was observed, although the rate of death was lower in DES 
patients. Numerous previous studies comparing PCI with 
DES to CABG in LMCAD patients have also documented 
no differences in MACCE occurrence. However, the rate of 
TVR in patients undergoing PCI in these studies was higher 
than for those undergoing CABG (ARTS II, MAIN COM-
PARE, SYNTAX, LE MANS). Similar results for TVR oc-
currence were reported by Seung, et al.9 In the present 
study, CABG was also significantly more effective than 
DES implantation at reducing the need for TVR revascular-
ization. A non-significant trend in this direction for patients 
with BMSs was observed. There were two cases of TVR in 
patients with DESs (6%) and four cases of TVR in patients 
with BMSs (8%), for a total TVR of 7% in PCI patients 
and 4% in CABG patients. For comparison, in prior regis-
tries and studies, TVR after LMCAD-stenting with DESs 
and BMSs ranged from 5.5% to 6% and from 11.7% to 
23%, respectively.19-22 Other authors have reported rates of 
TVR in PCI with DES and CABG groups at 6-14 months 
follow-up similar to the present study.5-7,23 The higher rate 
of TVR with PCI compared to CABG appeared to translate 
into a significant increase in the rate of death, but only in 
BMS patients. The higher rate of TVR in PCI with DES pa-
tients compared to CABG patients was not reflected in an 
overall increase in death or myocardial infarction. More-
over, patients died more frequently after CABG. The risk of 
TVR in PCI should be balanced against the invasiveness of 
surgical procedures and the risk of stroke related to CABG 
(2% vs. 0% in the PCI group, p=0.03 in current study), 
which has been found by numerous previous studies to be 
more common in this group.4,7 The lower rate of stroke af-
ter PCI may be due to the more frequent use of dual anti-
platelet therapy after stent implantation than after surgery, 
reflecting the differences in current guidelines and standard 
care between the two groups.24 The use of thienopyridine 
(ticlopidine or clopidogrel) at follow-up reached 64% in 
PCI patients, while only 10% of patients received such 
treatment after CABG. A comparable rate of patients re-
ceiving thienopyridine one year after PCI was reported in 
the SYNTAX Trial (71.1%).4 However, the influence of 
drug therapy on reducing stroke occurrence is just a hy-Damian Kawecki, et al.
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ies, it is also limited by the selective performance of PCI in 
patients considered to be unsuitable for CABG.
Despite the fact that patients treated with PCI were at 
higher operative risk, PCI with DES for LMCAD was com-
parable to CABG in terms of mortality, ACS and stroke 
(MACCE) at midterm follow-up. PCI patients had a signifi-
cantly higher risk of TVR. PCI with DES is safe and could 
represent a good alternative to CABG for selected cases of 
patients with unprotected LMCAD.
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